nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP3A4—Fingolimod—multiple sclerosis	0.0752	0.172	CbGbCtD
Sitaxentan—CYP2C19—Prednisone—multiple sclerosis	0.0607	0.139	CbGbCtD
Sitaxentan—CYP3A4—Methylprednisolone—multiple sclerosis	0.0485	0.111	CbGbCtD
Sitaxentan—CYP2C19—Dexamethasone—multiple sclerosis	0.0379	0.0869	CbGbCtD
Sitaxentan—CYP3A4—Triamcinolone—multiple sclerosis	0.0367	0.0842	CbGbCtD
Sitaxentan—CYP3A4—Mitoxantrone—multiple sclerosis	0.0353	0.081	CbGbCtD
Sitaxentan—CYP2C9—Dexamethasone—multiple sclerosis	0.0315	0.0723	CbGbCtD
Sitaxentan—CYP3A4—Betamethasone—multiple sclerosis	0.0315	0.0722	CbGbCtD
Sitaxentan—CYP3A4—Prednisolone—multiple sclerosis	0.0311	0.0713	CbGbCtD
Sitaxentan—CYP3A4—Prednisone—multiple sclerosis	0.0294	0.0673	CbGbCtD
Sitaxentan—CYP3A4—Dexamethasone—multiple sclerosis	0.0183	0.042	CbGbCtD
Sitaxentan—EDNRB—Signaling by GPCR—S1PR1—multiple sclerosis	0.000539	0.00367	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—PTGER4—multiple sclerosis	0.000532	0.00362	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.000519	0.00353	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CXCR3—multiple sclerosis	0.000513	0.0035	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	0.000506	0.00344	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—RGS1—multiple sclerosis	0.000505	0.00344	CbGpPWpGaD
Sitaxentan—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000502	0.00342	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CCL5—multiple sclerosis	0.000501	0.00341	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.0005	0.0034	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CCR2—multiple sclerosis	0.000499	0.0034	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000493	0.00336	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—POMC—multiple sclerosis	0.000492	0.00335	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.000482	0.00329	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelins—MAPK1—multiple sclerosis	0.000482	0.00328	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CCL2—multiple sclerosis	0.000482	0.00328	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—GPR65—multiple sclerosis	0.000479	0.00326	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.000469	0.0032	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000469	0.00319	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CNR1—multiple sclerosis	0.000461	0.00314	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—RGS1—multiple sclerosis	0.000459	0.00312	CbGpPWpGaD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000453	0.00309	CbGpPWpGaD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000453	0.00309	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CCR5—multiple sclerosis	0.000451	0.00307	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CCR1—multiple sclerosis	0.000438	0.00298	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000438	0.00298	CbGpPWpGaD
Sitaxentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000437	0.00297	CbGpPWpGaD
Sitaxentan—CYP2C19—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000435	0.00297	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—GPR65—multiple sclerosis	0.000435	0.00296	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.000433	0.00295	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—S1PR1—multiple sclerosis	0.000425	0.0029	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000423	0.00288	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—LINGO1—multiple sclerosis	0.000421	0.00286	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CXCL10—multiple sclerosis	0.000415	0.00283	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—CYP27B1—multiple sclerosis	0.0004	0.00273	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—CYP24A1—multiple sclerosis	0.0004	0.00273	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CXCL13—multiple sclerosis	0.000398	0.00271	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CCR1—multiple sclerosis	0.000398	0.00271	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	0.000396	0.0027	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CCL3—multiple sclerosis	0.000395	0.00269	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000395	0.00269	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000395	0.00269	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.00039	0.00266	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—S1PR1—multiple sclerosis	0.000386	0.00263	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—PTGER4—multiple sclerosis	0.00038	0.00259	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CXCR3—multiple sclerosis	0.000367	0.0025	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000365	0.00249	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000365	0.00249	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TAGAP—multiple sclerosis	0.000365	0.00248	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—RGS1—multiple sclerosis	0.000362	0.00246	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00036	0.00245	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00036	0.00245	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CCR2—multiple sclerosis	0.000357	0.00243	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CCL5—multiple sclerosis	0.000357	0.00243	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000353	0.0024	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—POMC—multiple sclerosis	0.000352	0.0024	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CCL2—multiple sclerosis	0.000345	0.00235	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—GPR65—multiple sclerosis	0.000343	0.00233	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000336	0.00229	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.00033	0.00225	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CNR1—multiple sclerosis	0.00033	0.00225	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—RGS1—multiple sclerosis	0.000328	0.00224	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000323	0.0022	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CCR5—multiple sclerosis	0.000322	0.00219	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—S1PR1—multiple sclerosis	0.000319	0.00217	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CCR1—multiple sclerosis	0.000313	0.00213	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000313	0.00213	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—GPR65—multiple sclerosis	0.000311	0.00212	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—GPC5—multiple sclerosis	0.00031	0.00211	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000302	0.00206	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—LINGO1—multiple sclerosis	0.000301	0.00205	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—PTGER4—multiple sclerosis	0.0003	0.00205	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CXCL10—multiple sclerosis	0.000297	0.00202	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CXCR3—multiple sclerosis	0.00029	0.00198	CbGpPWpGaD
Sitaxentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000288	0.00196	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CCR1—multiple sclerosis	0.000285	0.00194	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CXCL13—multiple sclerosis	0.000285	0.00194	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	0.000284	0.00193	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CCL3—multiple sclerosis	0.000283	0.00193	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CCR2—multiple sclerosis	0.000282	0.00192	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PTGER4—multiple sclerosis	0.000273	0.00186	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—RGS1—multiple sclerosis	0.000271	0.00185	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CXCR3—multiple sclerosis	0.000263	0.00179	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TAGAP—multiple sclerosis	0.000261	0.00178	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CNR1—multiple sclerosis	0.00026	0.00177	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—GPR65—multiple sclerosis	0.000257	0.00175	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CCR2—multiple sclerosis	0.000256	0.00175	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CCL5—multiple sclerosis	0.000256	0.00174	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	0.000252	0.00172	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—POMC—multiple sclerosis	0.000252	0.00171	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CCL2—multiple sclerosis	0.000246	0.00168	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000241	0.00164	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000241	0.00164	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000237	0.00162	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000237	0.00162	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CNR1—multiple sclerosis	0.000237	0.00161	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000236	0.00161	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CXCL13—multiple sclerosis	0.000235	0.0016	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCR1—multiple sclerosis	0.000235	0.0016	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000235	0.0016	CbGpPWpGaD
Sitaxentan—Eye disorder—Betamethasone—multiple sclerosis	0.000231	0.000555	CcSEcCtD
Sitaxentan—Eye disorder—Dexamethasone—multiple sclerosis	0.000231	0.000555	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000231	0.00157	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CCR5—multiple sclerosis	0.00023	0.00157	CbGpPWpGaD
Sitaxentan—Somnolence—Mitoxantrone—multiple sclerosis	0.000228	0.000548	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—S1PR1—multiple sclerosis	0.000228	0.00155	CbGpPWpGaD
Sitaxentan—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000226	0.000542	CcSEcCtD
Sitaxentan—Asthma—Methotrexate—multiple sclerosis	0.000225	0.00054	CcSEcCtD
Sitaxentan—Angiopathy—Betamethasone—multiple sclerosis	0.000225	0.000539	CcSEcCtD
Sitaxentan—Angiopathy—Dexamethasone—multiple sclerosis	0.000225	0.000539	CcSEcCtD
Sitaxentan—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000223	0.000536	CcSEcCtD
Sitaxentan—Eosinophilia—Methotrexate—multiple sclerosis	0.000223	0.000534	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—GPC5—multiple sclerosis	0.000222	0.00151	CbGpPWpGaD
Sitaxentan—Fatigue—Mitoxantrone—multiple sclerosis	0.000221	0.000531	CcSEcCtD
Sitaxentan—Ill-defined disorder—Triamcinolone—multiple sclerosis	0.00022	0.000528	CcSEcCtD
Sitaxentan—Ill-defined disorder—Methylprednisolone—multiple sclerosis	0.00022	0.000527	CcSEcCtD
Sitaxentan—Pain—Mitoxantrone—multiple sclerosis	0.00022	0.000527	CcSEcCtD
Sitaxentan—Constipation—Mitoxantrone—multiple sclerosis	0.00022	0.000527	CcSEcCtD
Sitaxentan—Bradycardia—Prednisone—multiple sclerosis	0.000219	0.000526	CcSEcCtD
Sitaxentan—Alopecia—Betamethasone—multiple sclerosis	0.000219	0.000525	CcSEcCtD
Sitaxentan—Alopecia—Dexamethasone—multiple sclerosis	0.000219	0.000525	CcSEcCtD
Sitaxentan—Diarrhoea—Azathioprine—multiple sclerosis	0.000217	0.000521	CcSEcCtD
Sitaxentan—Discomfort—Prednisolone—multiple sclerosis	0.000217	0.000521	CcSEcCtD
Sitaxentan—Haemoglobin—Prednisone—multiple sclerosis	0.000217	0.00052	CcSEcCtD
Sitaxentan—Abdominal discomfort—Methotrexate—multiple sclerosis	0.000216	0.000518	CcSEcCtD
Sitaxentan—Haemorrhage—Prednisone—multiple sclerosis	0.000216	0.000517	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000215	0.00146	CbGpPWpGaD
Sitaxentan—Malaise—Triamcinolone—multiple sclerosis	0.000214	0.000514	CcSEcCtD
Sitaxentan—Pancytopenia—Methotrexate—multiple sclerosis	0.000214	0.000513	CcSEcCtD
Sitaxentan—Malaise—Methylprednisolone—multiple sclerosis	0.000214	0.000512	CcSEcCtD
Sitaxentan—Vertigo—Triamcinolone—multiple sclerosis	0.000213	0.000512	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—CXCL10—multiple sclerosis	0.000213	0.00145	CbGpPWpGaD
Sitaxentan—Vertigo—Methylprednisolone—multiple sclerosis	0.000213	0.000511	CcSEcCtD
Sitaxentan—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000212	0.000508	CcSEcCtD
Sitaxentan—Oedema—Prednisolone—multiple sclerosis	0.000211	0.000505	CcSEcCtD
Sitaxentan—Dysuria—Methotrexate—multiple sclerosis	0.00021	0.000505	CcSEcCtD
Sitaxentan—Dizziness—Azathioprine—multiple sclerosis	0.00021	0.000504	CcSEcCtD
Sitaxentan—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000209	0.00142	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000208	0.00141	CbGpPWpGaD
Sitaxentan—Tachycardia—Prednisolone—multiple sclerosis	0.000206	0.000493	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Methotrexate—multiple sclerosis	0.000205	0.000493	CcSEcCtD
Sitaxentan—Urticaria—Mitoxantrone—multiple sclerosis	0.000204	0.000489	CcSEcCtD
Sitaxentan—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000203	0.000487	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CCL3—multiple sclerosis	0.000203	0.00138	CbGpPWpGaD
Sitaxentan—Vomiting—Azathioprine—multiple sclerosis	0.000202	0.000485	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—CCR2—multiple sclerosis	0.000202	0.00138	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CCL5—multiple sclerosis	0.000202	0.00137	CbGpPWpGaD
Sitaxentan—Eye disorder—Prednisone—multiple sclerosis	0.000201	0.000483	CcSEcCtD
Sitaxentan—Infestation—Methotrexate—multiple sclerosis	0.000201	0.000481	CcSEcCtD
Sitaxentan—Infestation NOS—Methotrexate—multiple sclerosis	0.000201	0.000481	CcSEcCtD
Sitaxentan—Rash—Azathioprine—multiple sclerosis	0.0002	0.000481	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.0002	0.00048	CcSEcCtD
Sitaxentan—Dermatitis—Azathioprine—multiple sclerosis	0.0002	0.00048	CcSEcCtD
Sitaxentan—Flushing—Prednisone—multiple sclerosis	0.0002	0.00048	CcSEcCtD
Sitaxentan—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.0002	0.000479	CcSEcCtD
Sitaxentan—Ill-defined disorder—Betamethasone—multiple sclerosis	0.0002	0.000479	CcSEcCtD
Sitaxentan—Discomfort—Triamcinolone—multiple sclerosis	0.0002	0.000479	CcSEcCtD
Sitaxentan—Discomfort—Methylprednisolone—multiple sclerosis	0.000199	0.000478	CcSEcCtD
Sitaxentan—Headache—Azathioprine—multiple sclerosis	0.000199	0.000477	CcSEcCtD
Sitaxentan—Dry mouth—Triamcinolone—multiple sclerosis	0.000198	0.000474	CcSEcCtD
Sitaxentan—Renal failure—Methotrexate—multiple sclerosis	0.000197	0.000473	CcSEcCtD
Sitaxentan—Stomatitis—Methotrexate—multiple sclerosis	0.000196	0.000469	CcSEcCtD
Sitaxentan—Angiopathy—Prednisone—multiple sclerosis	0.000196	0.000469	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—PTGER4—multiple sclerosis	0.000195	0.00133	CbGpPWpGaD
Sitaxentan—Conjunctivitis—Methotrexate—multiple sclerosis	0.000195	0.000468	CcSEcCtD
Sitaxentan—Confusional state—Methylprednisolone—multiple sclerosis	0.000195	0.000468	CcSEcCtD
Sitaxentan—Immune system disorder—Prednisone—multiple sclerosis	0.000195	0.000467	CcSEcCtD
Sitaxentan—Malaise—Betamethasone—multiple sclerosis	0.000194	0.000466	CcSEcCtD
Sitaxentan—Malaise—Dexamethasone—multiple sclerosis	0.000194	0.000466	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—RGS1—multiple sclerosis	0.000194	0.00132	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	0.000194	0.00132	CbGpPWpGaD
Sitaxentan—Oedema—Triamcinolone—multiple sclerosis	0.000194	0.000465	CcSEcCtD
Sitaxentan—Vertigo—Betamethasone—multiple sclerosis	0.000194	0.000464	CcSEcCtD
Sitaxentan—Vertigo—Dexamethasone—multiple sclerosis	0.000194	0.000464	CcSEcCtD
Sitaxentan—Infection—Triamcinolone—multiple sclerosis	0.000193	0.000462	CcSEcCtD
Sitaxentan—Infection—Methylprednisolone—multiple sclerosis	0.000192	0.000461	CcSEcCtD
Sitaxentan—Haematuria—Methotrexate—multiple sclerosis	0.000191	0.000459	CcSEcCtD
Sitaxentan—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000191	0.0013	CbGpPWpGaD
Sitaxentan—Insomnia—Prednisolone—multiple sclerosis	0.000191	0.000457	CcSEcCtD
Sitaxentan—Alopecia—Prednisone—multiple sclerosis	0.00019	0.000457	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.00019	0.000455	CcSEcCtD
Sitaxentan—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.00019	0.000455	CcSEcCtD
Sitaxentan—Epistaxis—Methotrexate—multiple sclerosis	0.000189	0.000454	CcSEcCtD
Sitaxentan—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000189	0.000454	CcSEcCtD
Sitaxentan—Tachycardia—Triamcinolone—multiple sclerosis	0.000189	0.000454	CcSEcCtD
Sitaxentan—Mental disorder—Prednisone—multiple sclerosis	0.000189	0.000453	CcSEcCtD
Sitaxentan—Nausea—Azathioprine—multiple sclerosis	0.000189	0.000453	CcSEcCtD
Sitaxentan—Tachycardia—Methylprednisolone—multiple sclerosis	0.000189	0.000453	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CXCR3—multiple sclerosis	0.000189	0.00128	CbGpPWpGaD
Sitaxentan—Skin disorder—Methylprednisolone—multiple sclerosis	0.000188	0.000451	CcSEcCtD
Sitaxentan—Malnutrition—Prednisone—multiple sclerosis	0.000188	0.00045	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—CNR1—multiple sclerosis	0.000186	0.00127	CbGpPWpGaD
Sitaxentan—Asthenia—Mitoxantrone—multiple sclerosis	0.000184	0.000442	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—GPR65—multiple sclerosis	0.000184	0.00125	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CCR2—multiple sclerosis	0.000183	0.00125	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CCL5—multiple sclerosis	0.000183	0.00125	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CCR5—multiple sclerosis	0.000182	0.00124	CbGpPWpGaD
Sitaxentan—Discomfort—Dexamethasone—multiple sclerosis	0.000181	0.000435	CcSEcCtD
Sitaxentan—Discomfort—Betamethasone—multiple sclerosis	0.000181	0.000435	CcSEcCtD
Sitaxentan—Haemoglobin—Methotrexate—multiple sclerosis	0.000181	0.000434	CcSEcCtD
Sitaxentan—Hypotension—Methylprednisolone—multiple sclerosis	0.000181	0.000433	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	0.000181	0.00123	CbGpPWpGaD
Sitaxentan—Pain—Prednisolone—multiple sclerosis	0.00018	0.000432	CcSEcCtD
Sitaxentan—Haemorrhage—Methotrexate—multiple sclerosis	0.00018	0.000432	CcSEcCtD
Sitaxentan—Hepatitis—Methotrexate—multiple sclerosis	0.00018	0.000432	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—POMC—multiple sclerosis	0.00018	0.00123	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000179	0.00122	CbGpPWpGaD
Sitaxentan—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000178	0.000427	CcSEcCtD
Sitaxentan—Urethral disorder—Methotrexate—multiple sclerosis	0.000177	0.000424	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—CCL2—multiple sclerosis	0.000176	0.0012	CbGpPWpGaD
Sitaxentan—Oedema—Betamethasone—multiple sclerosis	0.000176	0.000422	CcSEcCtD
Sitaxentan—Oedema—Dexamethasone—multiple sclerosis	0.000176	0.000422	CcSEcCtD
Sitaxentan—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000176	0.000422	CcSEcCtD
Sitaxentan—Insomnia—Triamcinolone—multiple sclerosis	0.000175	0.00042	CcSEcCtD
Sitaxentan—Insomnia—Methylprednisolone—multiple sclerosis	0.000175	0.000419	CcSEcCtD
Sitaxentan—Infection—Betamethasone—multiple sclerosis	0.000175	0.000419	CcSEcCtD
Sitaxentan—Infection—Dexamethasone—multiple sclerosis	0.000175	0.000419	CcSEcCtD
Sitaxentan—Ill-defined disorder—Prednisone—multiple sclerosis	0.000174	0.000418	CcSEcCtD
Sitaxentan—Feeling abnormal—Prednisolone—multiple sclerosis	0.000174	0.000417	CcSEcCtD
Sitaxentan—Visual impairment—Methotrexate—multiple sclerosis	0.000174	0.000416	CcSEcCtD
Sitaxentan—Anaemia—Prednisone—multiple sclerosis	0.000173	0.000416	CcSEcCtD
Sitaxentan—Nervous system disorder—Betamethasone—multiple sclerosis	0.000172	0.000414	CcSEcCtD
Sitaxentan—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000172	0.000414	CcSEcCtD
Sitaxentan—Agitation—Prednisone—multiple sclerosis	0.000172	0.000414	CcSEcCtD
Sitaxentan—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000172	0.000413	CcSEcCtD
Sitaxentan—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000172	0.000413	CcSEcCtD
Sitaxentan—Tachycardia—Betamethasone—multiple sclerosis	0.000172	0.000412	CcSEcCtD
Sitaxentan—Tachycardia—Dexamethasone—multiple sclerosis	0.000172	0.000412	CcSEcCtD
Sitaxentan—Dyspepsia—Triamcinolone—multiple sclerosis	0.000171	0.000409	CcSEcCtD
Sitaxentan—Dyspepsia—Methylprednisolone—multiple sclerosis	0.00017	0.000408	CcSEcCtD
Sitaxentan—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.00017	0.00115	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CNR1—multiple sclerosis	0.000169	0.00115	CbGpPWpGaD
Sitaxentan—Malaise—Prednisone—multiple sclerosis	0.000169	0.000406	CcSEcCtD
Sitaxentan—Vertigo—Prednisone—multiple sclerosis	0.000169	0.000404	CcSEcCtD
Sitaxentan—Eye disorder—Methotrexate—multiple sclerosis	0.000168	0.000404	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CXCL13—multiple sclerosis	0.000168	0.00114	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCR1—multiple sclerosis	0.000168	0.00114	CbGpPWpGaD
Sitaxentan—Tinnitus—Methotrexate—multiple sclerosis	0.000168	0.000403	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000168	0.00114	CbGpPWpGaD
Sitaxentan—Anorexia—Betamethasone—multiple sclerosis	0.000168	0.000402	CcSEcCtD
Sitaxentan—Anorexia—Dexamethasone—multiple sclerosis	0.000168	0.000402	CcSEcCtD
Sitaxentan—Urticaria—Prednisolone—multiple sclerosis	0.000167	0.000402	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CCL3—multiple sclerosis	0.000167	0.00114	CbGpPWpGaD
Sitaxentan—Cardiac disorder—Methotrexate—multiple sclerosis	0.000167	0.000401	CcSEcCtD
Sitaxentan—Fatigue—Triamcinolone—multiple sclerosis	0.000167	0.000401	CcSEcCtD
Sitaxentan—Fatigue—Methylprednisolone—multiple sclerosis	0.000167	0.0004	CcSEcCtD
Sitaxentan—Pain—Triamcinolone—multiple sclerosis	0.000166	0.000398	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—CCR5—multiple sclerosis	0.000165	0.00112	CbGpPWpGaD
Sitaxentan—Hypotension—Betamethasone—multiple sclerosis	0.000164	0.000394	CcSEcCtD
Sitaxentan—Hypotension—Dexamethasone—multiple sclerosis	0.000164	0.000394	CcSEcCtD
Sitaxentan—Angiopathy—Methotrexate—multiple sclerosis	0.000163	0.000392	CcSEcCtD
Sitaxentan—Vomiting—Mitoxantrone—multiple sclerosis	0.000163	0.000392	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—IL2RA—multiple sclerosis	0.000163	0.00111	CbGpPWpGaD
Sitaxentan—Immune system disorder—Methotrexate—multiple sclerosis	0.000163	0.00039	CcSEcCtD
Sitaxentan—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000162	0.000389	CcSEcCtD
Sitaxentan—Rash—Mitoxantrone—multiple sclerosis	0.000162	0.000388	CcSEcCtD
Sitaxentan—Dermatitis—Mitoxantrone—multiple sclerosis	0.000162	0.000388	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—PTGER4—multiple sclerosis	0.000161	0.0011	CbGpPWpGaD
Sitaxentan—Headache—Mitoxantrone—multiple sclerosis	0.000161	0.000386	CcSEcCtD
Sitaxentan—Feeling abnormal—Triamcinolone—multiple sclerosis	0.00016	0.000383	CcSEcCtD
Sitaxentan—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000159	0.000382	CcSEcCtD
Sitaxentan—Alopecia—Methotrexate—multiple sclerosis	0.000159	0.000382	CcSEcCtD
Sitaxentan—Insomnia—Dexamethasone—multiple sclerosis	0.000159	0.000381	CcSEcCtD
Sitaxentan—Insomnia—Betamethasone—multiple sclerosis	0.000159	0.000381	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—PGR—multiple sclerosis	0.000159	0.00108	CbGpPWpGaD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000159	0.000381	CcSEcCtD
Sitaxentan—Discomfort—Prednisone—multiple sclerosis	0.000158	0.000379	CcSEcCtD
Sitaxentan—Mental disorder—Methotrexate—multiple sclerosis	0.000158	0.000379	CcSEcCtD
Sitaxentan—Malnutrition—Methotrexate—multiple sclerosis	0.000157	0.000376	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CXCR3—multiple sclerosis	0.000156	0.00106	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Prednisolone—multiple sclerosis	0.000155	0.000372	CcSEcCtD
Sitaxentan—Dyspepsia—Dexamethasone—multiple sclerosis	0.000155	0.000371	CcSEcCtD
Sitaxentan—Dyspepsia—Betamethasone—multiple sclerosis	0.000155	0.000371	CcSEcCtD
Sitaxentan—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000155	0.00105	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CD28—multiple sclerosis	0.000154	0.00105	CbGpPWpGaD
Sitaxentan—Urticaria—Triamcinolone—multiple sclerosis	0.000154	0.000369	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000154	0.00105	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000154	0.00105	CbGpPWpGaD
Sitaxentan—Urticaria—Methylprednisolone—multiple sclerosis	0.000154	0.000368	CcSEcCtD
Sitaxentan—Body temperature increased—Triamcinolone—multiple sclerosis	0.000153	0.000367	CcSEcCtD
Sitaxentan—Oedema—Prednisone—multiple sclerosis	0.000153	0.000367	CcSEcCtD
Sitaxentan—Decreased appetite—Betamethasone—multiple sclerosis	0.000153	0.000367	CcSEcCtD
Sitaxentan—Decreased appetite—Dexamethasone—multiple sclerosis	0.000153	0.000367	CcSEcCtD
Sitaxentan—Nausea—Mitoxantrone—multiple sclerosis	0.000153	0.000366	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CXCL10—multiple sclerosis	0.000152	0.00104	CbGpPWpGaD
Sitaxentan—Infection—Prednisone—multiple sclerosis	0.000152	0.000365	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000152	0.000364	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000152	0.000364	CcSEcCtD
Sitaxentan—Fatigue—Dexamethasone—multiple sclerosis	0.000152	0.000364	CcSEcCtD
Sitaxentan—Fatigue—Betamethasone—multiple sclerosis	0.000152	0.000364	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CCR2—multiple sclerosis	0.000151	0.00103	CbGpPWpGaD
Sitaxentan—Pain—Betamethasone—multiple sclerosis	0.00015	0.000361	CcSEcCtD
Sitaxentan—Pain—Dexamethasone—multiple sclerosis	0.00015	0.000361	CcSEcCtD
Sitaxentan—Nervous system disorder—Prednisone—multiple sclerosis	0.00015	0.00036	CcSEcCtD
Sitaxentan—Tachycardia—Prednisone—multiple sclerosis	0.000149	0.000358	CcSEcCtD
Sitaxentan—Skin disorder—Prednisone—multiple sclerosis	0.000149	0.000357	CcSEcCtD
Sitaxentan—Anorexia—Prednisone—multiple sclerosis	0.000146	0.00035	CcSEcCtD
Sitaxentan—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000146	0.000349	CcSEcCtD
Sitaxentan—Anaemia—Methotrexate—multiple sclerosis	0.000145	0.000348	CcSEcCtD
Sitaxentan—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000145	0.000348	CcSEcCtD
Sitaxentan—Feeling abnormal—Betamethasone—multiple sclerosis	0.000145	0.000348	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—CCL5—multiple sclerosis	0.000144	0.000984	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000143	0.000342	CcSEcCtD
Sitaxentan—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000142	0.000342	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—POMC—multiple sclerosis	0.000142	0.000968	CbGpPWpGaD
Sitaxentan—Malaise—Methotrexate—multiple sclerosis	0.000141	0.000339	CcSEcCtD
Sitaxentan—Vertigo—Methotrexate—multiple sclerosis	0.000141	0.000338	CcSEcCtD
Sitaxentan—Leukopenia—Methotrexate—multiple sclerosis	0.00014	0.000337	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.00014	0.000954	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.00014	0.000954	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CNR1—multiple sclerosis	0.00014	0.000951	CbGpPWpGaD
Sitaxentan—Urticaria—Dexamethasone—multiple sclerosis	0.00014	0.000335	CcSEcCtD
Sitaxentan—Urticaria—Betamethasone—multiple sclerosis	0.00014	0.000335	CcSEcCtD
Sitaxentan—Dizziness—Prednisolone—multiple sclerosis	0.000139	0.000334	CcSEcCtD
Sitaxentan—Asthenia—Triamcinolone—multiple sclerosis	0.000139	0.000334	CcSEcCtD
Sitaxentan—Body temperature increased—Betamethasone—multiple sclerosis	0.000139	0.000333	CcSEcCtD
Sitaxentan—Body temperature increased—Dexamethasone—multiple sclerosis	0.000139	0.000333	CcSEcCtD
Sitaxentan—Asthenia—Methylprednisolone—multiple sclerosis	0.000139	0.000333	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	0.000139	0.000945	CbGpPWpGaD
Sitaxentan—Insomnia—Prednisone—multiple sclerosis	0.000139	0.000332	CcSEcCtD
Sitaxentan—Dyspepsia—Prednisone—multiple sclerosis	0.000135	0.000323	CcSEcCtD
Sitaxentan—Chest pain—Methotrexate—multiple sclerosis	0.000134	0.00032	CcSEcCtD
Sitaxentan—Decreased appetite—Prednisone—multiple sclerosis	0.000133	0.000319	CcSEcCtD
Sitaxentan—Rash—Prednisolone—multiple sclerosis	0.000133	0.000319	CcSEcCtD
Sitaxentan—Dermatitis—Prednisolone—multiple sclerosis	0.000133	0.000318	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000133	0.000318	CcSEcCtD
Sitaxentan—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000132	0.000317	CcSEcCtD
Sitaxentan—Fatigue—Prednisone—multiple sclerosis	0.000132	0.000317	CcSEcCtD
Sitaxentan—Headache—Prednisolone—multiple sclerosis	0.000132	0.000317	CcSEcCtD
Sitaxentan—Discomfort—Methotrexate—multiple sclerosis	0.000132	0.000316	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CCL5—multiple sclerosis	0.000131	0.000893	CbGpPWpGaD
Sitaxentan—Constipation—Prednisone—multiple sclerosis	0.000131	0.000314	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—CCR5—multiple sclerosis	0.00013	0.000886	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—POMC—multiple sclerosis	0.000129	0.000879	CbGpPWpGaD
Sitaxentan—Confusional state—Methotrexate—multiple sclerosis	0.000129	0.00031	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000128	0.000873	CbGpPWpGaD
Sitaxentan—Dizziness—Triamcinolone—multiple sclerosis	0.000128	0.000307	CcSEcCtD
Sitaxentan—Dizziness—Methylprednisolone—multiple sclerosis	0.000128	0.000307	CcSEcCtD
Sitaxentan—Infection—Methotrexate—multiple sclerosis	0.000127	0.000305	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—CCL2—multiple sclerosis	0.000126	0.00086	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Prednisone—multiple sclerosis	0.000126	0.000303	CcSEcCtD
Sitaxentan—Asthenia—Betamethasone—multiple sclerosis	0.000126	0.000303	CcSEcCtD
Sitaxentan—Asthenia—Dexamethasone—multiple sclerosis	0.000126	0.000303	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CXCL10—multiple sclerosis	0.000126	0.000857	CbGpPWpGaD
Sitaxentan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000126	0.000856	CbGpPWpGaD
Sitaxentan—Nervous system disorder—Methotrexate—multiple sclerosis	0.000126	0.000301	CcSEcCtD
Sitaxentan—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000125	0.000301	CcSEcCtD
Sitaxentan—Nausea—Prednisolone—multiple sclerosis	0.000125	0.0003	CcSEcCtD
Sitaxentan—Skin disorder—Methotrexate—multiple sclerosis	0.000124	0.000298	CcSEcCtD
Sitaxentan—Vomiting—Triamcinolone—multiple sclerosis	0.000123	0.000296	CcSEcCtD
Sitaxentan—Vomiting—Methylprednisolone—multiple sclerosis	0.000123	0.000295	CcSEcCtD
Sitaxentan—Rash—Triamcinolone—multiple sclerosis	0.000122	0.000293	CcSEcCtD
Sitaxentan—Dermatitis—Triamcinolone—multiple sclerosis	0.000122	0.000293	CcSEcCtD
Sitaxentan—Anorexia—Methotrexate—multiple sclerosis	0.000122	0.000293	CcSEcCtD
Sitaxentan—Rash—Methylprednisolone—multiple sclerosis	0.000122	0.000292	CcSEcCtD
Sitaxentan—Dermatitis—Methylprednisolone—multiple sclerosis	0.000122	0.000292	CcSEcCtD
Sitaxentan—Urticaria—Prednisone—multiple sclerosis	0.000122	0.000292	CcSEcCtD
Sitaxentan—Headache—Triamcinolone—multiple sclerosis	0.000121	0.000291	CcSEcCtD
Sitaxentan—Headache—Methylprednisolone—multiple sclerosis	0.000121	0.000291	CcSEcCtD
Sitaxentan—Body temperature increased—Prednisone—multiple sclerosis	0.000121	0.00029	CcSEcCtD
Sitaxentan—Diarrhoea—Betamethasone—multiple sclerosis	0.00012	0.000289	CcSEcCtD
Sitaxentan—Diarrhoea—Dexamethasone—multiple sclerosis	0.00012	0.000289	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CCL3—multiple sclerosis	0.00012	0.000816	CbGpPWpGaD
Sitaxentan—Hypotension—Methotrexate—multiple sclerosis	0.00012	0.000287	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CCR5—multiple sclerosis	0.000118	0.000805	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL2RA—multiple sclerosis	0.000116	0.000793	CbGpPWpGaD
Sitaxentan—Dizziness—Betamethasone—multiple sclerosis	0.000116	0.000279	CcSEcCtD
Sitaxentan—Dizziness—Dexamethasone—multiple sclerosis	0.000116	0.000279	CcSEcCtD
Sitaxentan—Insomnia—Methotrexate—multiple sclerosis	0.000116	0.000278	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—PTGER4—multiple sclerosis	0.000115	0.000785	CbGpPWpGaD
Sitaxentan—Nausea—Triamcinolone—multiple sclerosis	0.000115	0.000276	CcSEcCtD
Sitaxentan—Nausea—Methylprednisolone—multiple sclerosis	0.000115	0.000275	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—TYK2—multiple sclerosis	0.000115	0.000781	CbGpPWpGaD
Sitaxentan—Somnolence—Methotrexate—multiple sclerosis	0.000114	0.000273	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—PGR—multiple sclerosis	0.000114	0.000773	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Prednisone—multiple sclerosis	0.000113	0.000271	CcSEcCtD
Sitaxentan—Dyspepsia—Methotrexate—multiple sclerosis	0.000113	0.00027	CcSEcCtD
Sitaxentan—Vomiting—Betamethasone—multiple sclerosis	0.000112	0.000268	CcSEcCtD
Sitaxentan—Vomiting—Dexamethasone—multiple sclerosis	0.000112	0.000268	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CXCR3—multiple sclerosis	0.000111	0.000758	CbGpPWpGaD
Sitaxentan—Decreased appetite—Methotrexate—multiple sclerosis	0.000111	0.000267	CcSEcCtD
Sitaxentan—Rash—Betamethasone—multiple sclerosis	0.000111	0.000266	CcSEcCtD
Sitaxentan—Rash—Dexamethasone—multiple sclerosis	0.000111	0.000266	CcSEcCtD
Sitaxentan—Dermatitis—Betamethasone—multiple sclerosis	0.000111	0.000266	CcSEcCtD
Sitaxentan—Dermatitis—Dexamethasone—multiple sclerosis	0.000111	0.000266	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000111	0.000265	CcSEcCtD
Sitaxentan—Fatigue—Methotrexate—multiple sclerosis	0.00011	0.000265	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CD28—multiple sclerosis	0.00011	0.000751	CbGpPWpGaD
Sitaxentan—Headache—Betamethasone—multiple sclerosis	0.00011	0.000264	CcSEcCtD
Sitaxentan—Headache—Dexamethasone—multiple sclerosis	0.00011	0.000264	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CD86—multiple sclerosis	0.00011	0.000749	CbGpPWpGaD
Sitaxentan—Asthenia—Prednisone—multiple sclerosis	0.00011	0.000264	CcSEcCtD
Sitaxentan—Pain—Methotrexate—multiple sclerosis	0.000109	0.000263	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CCR2—multiple sclerosis	0.000108	0.000738	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCL5—multiple sclerosis	0.000108	0.000737	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Methotrexate—multiple sclerosis	0.000105	0.000253	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—IL2—multiple sclerosis	0.000105	0.000715	CbGpPWpGaD
Sitaxentan—Diarrhoea—Prednisone—multiple sclerosis	0.000105	0.000251	CcSEcCtD
Sitaxentan—Nausea—Betamethasone—multiple sclerosis	0.000104	0.000251	CcSEcCtD
Sitaxentan—Nausea—Dexamethasone—multiple sclerosis	0.000104	0.000251	CcSEcCtD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000102	0.000694	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—POMC—multiple sclerosis	0.000102	0.000693	CbGpPWpGaD
Sitaxentan—Urticaria—Methotrexate—multiple sclerosis	0.000102	0.000244	CcSEcCtD
Sitaxentan—Dizziness—Prednisone—multiple sclerosis	0.000101	0.000243	CcSEcCtD
Sitaxentan—Body temperature increased—Methotrexate—multiple sclerosis	0.000101	0.000243	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—SPP1—multiple sclerosis	0.0001	0.000683	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CNR1—multiple sclerosis	0.0001	0.000681	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCR5—multiple sclerosis	9.76e-05	0.000664	CbGpPWpGaD
Sitaxentan—Vomiting—Prednisone—multiple sclerosis	9.74e-05	0.000234	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—SRM—multiple sclerosis	9.72e-05	0.000662	CbGpPWpGaD
Sitaxentan—Rash—Prednisone—multiple sclerosis	9.66e-05	0.000232	CcSEcCtD
Sitaxentan—Dermatitis—Prednisone—multiple sclerosis	9.65e-05	0.000231	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—IL2RA—multiple sclerosis	9.62e-05	0.000655	CbGpPWpGaD
Sitaxentan—Headache—Prednisone—multiple sclerosis	9.59e-05	0.00023	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—IL2—multiple sclerosis	9.54e-05	0.00065	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Methotrexate—multiple sclerosis	9.43e-05	0.000226	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—POMC—multiple sclerosis	9.24e-05	0.000629	CbGpPWpGaD
Sitaxentan—Asthenia—Methotrexate—multiple sclerosis	9.18e-05	0.00022	CcSEcCtD
Sitaxentan—Nausea—Prednisone—multiple sclerosis	9.1e-05	0.000218	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CCL2—multiple sclerosis	9.04e-05	0.000615	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—POMC—multiple sclerosis	9e-05	0.000613	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CXCL10—multiple sclerosis	9e-05	0.000613	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—APOE—multiple sclerosis	8.88e-05	0.000604	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SRM—multiple sclerosis	8.86e-05	0.000603	CbGpPWpGaD
Sitaxentan—Diarrhoea—Methotrexate—multiple sclerosis	8.76e-05	0.00021	CcSEcCtD
Sitaxentan—Dizziness—Methotrexate—multiple sclerosis	8.46e-05	0.000203	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—POMC—multiple sclerosis	8.21e-05	0.000559	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—TYK2—multiple sclerosis	8.21e-05	0.000559	CbGpPWpGaD
Sitaxentan—Vomiting—Methotrexate—multiple sclerosis	8.14e-05	0.000195	CcSEcCtD
Sitaxentan—Rash—Methotrexate—multiple sclerosis	8.07e-05	0.000194	CcSEcCtD
Sitaxentan—Dermatitis—Methotrexate—multiple sclerosis	8.06e-05	0.000193	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CD80—multiple sclerosis	8.02e-05	0.000546	CbGpPWpGaD
Sitaxentan—Headache—Methotrexate—multiple sclerosis	8.02e-05	0.000192	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CD86—multiple sclerosis	7.87e-05	0.000536	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCL5—multiple sclerosis	7.75e-05	0.000528	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—POMC—multiple sclerosis	7.62e-05	0.000519	CbGpPWpGaD
Sitaxentan—Nausea—Methotrexate—multiple sclerosis	7.6e-05	0.000182	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—IL2—multiple sclerosis	7.52e-05	0.000512	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCL2—multiple sclerosis	7.46e-05	0.000508	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—MAPK1—multiple sclerosis	7.3e-05	0.000497	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SPP1—multiple sclerosis	7.18e-05	0.000489	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCR5—multiple sclerosis	6.98e-05	0.000475	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL2RA—multiple sclerosis	6.88e-05	0.000469	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	6.85e-05	0.000466	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	6.85e-05	0.000466	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL2—multiple sclerosis	6.83e-05	0.000465	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TYK2—multiple sclerosis	6.77e-05	0.000461	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	6.69e-05	0.000456	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—APOE—multiple sclerosis	6.35e-05	0.000433	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GPC5—multiple sclerosis	6.26e-05	0.000426	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	6.24e-05	0.000425	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	6.24e-05	0.000425	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	6.1e-05	0.000415	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SRM—multiple sclerosis	5.84e-05	0.000398	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CD80—multiple sclerosis	5.74e-05	0.000391	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GPC5—multiple sclerosis	5.71e-05	0.000389	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL2—multiple sclerosis	5.64e-05	0.000384	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—IL6—multiple sclerosis	5.61e-05	0.000382	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—POMC—multiple sclerosis	5.46e-05	0.000372	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—POMC—multiple sclerosis	5.41e-05	0.000369	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCL2—multiple sclerosis	5.34e-05	0.000364	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MMP9—multiple sclerosis	5.33e-05	0.000363	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—MAPK1—multiple sclerosis	5.22e-05	0.000356	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—RRM1—multiple sclerosis	5.19e-05	0.000353	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TYK2—multiple sclerosis	4.85e-05	0.00033	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—STAT3—multiple sclerosis	4.74e-05	0.000323	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—RRM1—multiple sclerosis	4.73e-05	0.000322	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MYC—multiple sclerosis	4.41e-05	0.0003	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TGFB1—multiple sclerosis	4.4e-05	0.000299	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MAPK1—multiple sclerosis	4.31e-05	0.000294	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	4.12e-05	0.00028	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	4.12e-05	0.00028	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL2—multiple sclerosis	4.03e-05	0.000275	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	4.03e-05	0.000274	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL6—multiple sclerosis	4.01e-05	0.000273	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MMP9—multiple sclerosis	3.82e-05	0.00026	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GPC5—multiple sclerosis	3.76e-05	0.000256	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.67e-05	0.00025	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	3.46e-05	0.000235	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—STAT3—multiple sclerosis	3.39e-05	0.000231	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL6—multiple sclerosis	3.31e-05	0.000226	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MYC—multiple sclerosis	3.15e-05	0.000215	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	3.15e-05	0.000215	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.15e-05	0.000215	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TGFB1—multiple sclerosis	3.15e-05	0.000214	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—RRM1—multiple sclerosis	3.12e-05	0.000212	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MAPK1—multiple sclerosis	3.09e-05	0.00021	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—BCHE—multiple sclerosis	2.98e-05	0.000203	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.87e-05	0.000196	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—BCHE—multiple sclerosis	2.72e-05	0.000185	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL6—multiple sclerosis	2.37e-05	0.000161	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—APOE—multiple sclerosis	1.79e-05	0.000122	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.79e-05	0.000122	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—APOE—multiple sclerosis	1.63e-05	0.000111	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—POMC—multiple sclerosis	1.54e-05	0.000105	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—POMC—multiple sclerosis	1.4e-05	9.56e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ALB—multiple sclerosis	1.4e-05	9.56e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ALB—multiple sclerosis	1.28e-05	8.72e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—APOE—multiple sclerosis	1.08e-05	7.34e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—POMC—multiple sclerosis	9.26e-06	6.31e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ALB—multiple sclerosis	8.44e-06	5.75e-05	CbGpPWpGaD
